Multimodal Characterization of Optic Neuritis in Demyelinating Disease: Clinical Phenotypes, Neuroimaging, and Visual Biomarkers
DOI:
https://doi.org/10.64784/335Palabras clave:
optic neuritis, multiple sclerosis, neuromyelitis optica spectrum disorder, NMOSD, MOGAD, AQP4-IgG, MOG-IgG, optical coherence tomography, magnetic resonance imaging, visual biomarkers, demyelinating disease, neuro-ophthalmologyResumen
Optic neuritis is a heterogeneous neuro-ophthalmological syndrome that may represent the first clinical manifestation of an underlying central nervous system demyelinating disease. This study analyzed the distinguishing characteristics of multiple sclerosis-associated optic neuritis, aquaporin-4 immunoglobulin G-positive neuromyelitis optica spectrum disorder, and myelin oligodendrocyte glycoprotein antibody-associated disease through an integrated assessment of clinical phenotype, magnetic resonance imaging, optical coherence tomography, visual function, and serological biomarkers. The analysis identified partially overlapping but clinically meaningful patterns among the three disorders. Multiple sclerosis-associated optic neuritis was more frequently characterized by unilateral painful visual loss, shorter focal optic nerve lesions, comparatively less severe chronic retinal neuroaxonal damage, and generally favorable recovery of high-contrast visual acuity. AQP4-IgG-positive neuromyelitis optica spectrum disorder was associated with more severe visual impairment, recurrent attacks, posterior or chiasmal optic pathway involvement, greater retinal nerve fiber and ganglion cell loss, and a higher risk of persistent visual disability. MOG antibody-associated disease more commonly exhibited bilateral optic neuritis, marked optic disc edema, extensive anterior optic nerve involvement, and pronounced inflammatory changes, while substantial visual recovery could occur despite severe initial visual loss. Optical coherence tomography and visual evoked potentials demonstrated that structural and functional abnormalities may persist even after apparent recovery of conventional visual acuity. The findings support a multimodal diagnostic model in which clinical examination, neuroimaging, retinal structural assessment, functional visual testing, and disease-associated antibodies provide complementary rather than redundant information. Early integration of these domains may improve etiological classification, reduce diagnostic uncertainty, and facilitate neurological follow-up in patients presenting with a first episode of optic neuritis.
Referencias
• Banwell, B., Bennett, J. L., Marignier, R., Kim, H. J., Brilot, F., Flanagan, E. P., Ramanathan, S., Waters, P., Tenembaum, S., Graves, J. S., Chitnis, T., Brandt, A. U., Hemingway, C., Neuteboom, R., Pandit, L., Reindl, M., Saiz, A., Sato, D. K., Rostasy, K., … Palace, J. (2023). Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria. The Lancet Neurology, 22(3), 268–282. doi:10.1016/S1474-4422(22)00431-8.
• Benard-Seguin, E., & Costello, F. (2023). Optic neuritis: Current challenges in diagnosis and management. Current Opinion in Neurology, 36(1), 10–18. doi:10.1097/WCO.0000000000001128.
• Bergeron, E., & Bouffard, M. A. (2024). Evidence-based management of optic neuritis. Current Opinion in Ophthalmology, 35(1), 73–82. doi:10.1097/ICU.0000000000001007.
• Chen, J. J., Tobin, W. O., Majed, M., Jitprapaikulsan, J., Fryer, J. P., Leavitt, J. A., Flanagan, E. P., McKeon, A., & Pittock, S. J. (2018). Prevalence of myelin oligodendrocyte glycoprotein and aquaporin-4-IgG in patients in the Optic Neuritis Treatment Trial. JAMA Ophthalmology, 136(4), 419–422. doi:10.1001/jamaophthalmol.2017.6757.
• Costello, F., Coupland, S., Hodge, W., Lorello, G. R., Koroluk, J., Pan, Y. I., Freedman, M. S., Zackon, D. H., & Kardon, R. H. (2006). Quantifying axonal loss after optic neuritis with optical coherence tomography. Annals of Neurology, 59(6), 963–969. doi:10.1002/ana.20851.
• Costello, F. E., Klistorner, A., & Kardon, R. (2011). Optical coherence tomography in the diagnosis and management of optic neuritis and multiple sclerosis. Ophthalmic Surgery, Lasers & Imaging, 42(Suppl.), S28–S40. doi:10.3928/15428877-20110627-03.
• Darakdjian, M., Chaves, H., Hernandez, J., & Cejas, C. (2023). MRI pattern in acute optic neuritis: Comparing multiple sclerosis, NMO and MOGAD. The Neuroradiology Journal, 36(3), 267–272. doi:10.1177/19714009221124308.
• Frohman, E., Costello, F., Zivadinov, R., Stuve, O., Conger, A., Winslow, H., Trip, A., Frohman, T., & Balcer, L. (2006). Optical coherence tomography in multiple sclerosis. The Lancet Neurology, 5(10), 853–863. doi:10.1016/S1474-4422(06)70573-7.
• Jamali Dogahe, S., Pakravan, P., & Pakravan, M. (2023). Acute optic neuritis: An update on approach and management. Journal of Ophthalmic & Vision Research, 18(4), 433–440. doi:10.18502/jovr.v18i4.14556.
• Kallenbach, K., & Frederiksen, J. (2007). Optical coherence tomography in optic neuritis and multiple sclerosis: A review. European Journal of Neurology, 14(8), 841–849. doi:10.1111/j.1468-1331.2007.01736.x.
• Kraker, J. A., & Chen, J. J. (2023). An update on optic neuritis. Journal of Neurology, 270(10), 5113–5126. doi:10.1007/s00415-023-11920-x.
• Meng, Z., He, Y., Guo, K., & Li, L. (2025). Imaging biomarkers in optic neuritis: Current tools and future directions. Frontiers in Neurology, 16, 1666835. doi:10.3389/fneur.2025.1666835.
• Moheb, N., & Chen, J. J. (2023). The neuro-ophthalmological manifestations of NMOSD and MOGAD—A comprehensive review. Eye, 37(12), 2391–2398. doi:10.1038/s41433-023-02477-0.
• Optic Neuritis Study Group. (2008). Multiple sclerosis risk after optic neuritis: Final Optic Neuritis Treatment Trial follow-up. Archives of Neurology, 65(6), 727–732. doi:10.1001/archneur.65.6.727.
• Pasol, J., Feuer, W., Yang, C., Shaw, G., Kardon, R., & Guy, J. (2010). Phosphorylated neurofilament heavy chain correlations to visual function, optical coherence tomography, and treatment. Multiple Sclerosis International, 2010, 542691. doi:10.1155/2010/542691.
• Petzold, A., Fraser, C. L., Abegg, M., Alroughani, R., Alshowaeir, D., Alvarenga, R., Andris, C., Asgari, N., Barnett, Y., Battistella, R., Behbehani, R., Berger, T., Bikbov, M. M., Biotti, D., Biousse, V., Boschi, A., Brazdil, M., Brezhnev, A., Calabresi, P. A., … Plant, G. T. (2022). Diagnosis and classification of optic neuritis. The Lancet Neurology, 21(12), 1120–1134. doi:10.1016/S1474-4422(22)00200-9.
• Thompson, A. J., Banwell, B. L., Barkhof, F., Carroll, W. M., Coetzee, T., Comi, G., Correale, J., Fazekas, F., Filippi, M., Freedman, M. S., Fujihara, K., Galetta, S. L., Hartung, H. P., Kappos, L., Lublin, F. D., Marrie, R. A., Miller, A. E., Miller, D. H., Montalban, X., … Cohen, J. A. (2018). Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. The Lancet Neurology, 17(2), 162–173. doi:10.1016/S1474-4422(17)30470-2.
• Toosy, A. T., Mason, D. F., & Miller, D. H. (2014). Optic neuritis. The Lancet Neurology, 13(1), 83–99. doi:10.1016/S1474-4422(13)70259-X.
• Wingerchuk, D. M., Banwell, B., Bennett, J. L., Cabre, P., Carroll, W., Chitnis, T., de Seze, J., Fujihara, K., Greenberg, B., Jacob, A., Jarius, S., Lana-Peixoto, M., Levy, M., Simon, J. H., Tenembaum, S., Traboulsee, A. L., Waters, P., Wellik, K. E., Weinshenker, B. G., & International Panel for NMO Diagnosis. (2015). International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology, 85(2), 177–189. doi:10.1212/WNL.0000000000001729.
• Xu, S. C., Kardon, R. H., Leavitt, J. A., Flanagan, E. P., Pittock, S. J., & Chen, J. J. (2019). Optical coherence tomography is highly sensitive in detecting prior optic neuritis. Neurology, 92(6), e527–e535. doi:10.1212/WNL.0000000000006873.
